Travere Therapeutics, Inc. Common Stock TVTX
i
Market dataready · fetched 2026-11-12T17:13:30.138Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T17:13:08.974905509Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T17:13:29.654525+00:00
Travere Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 56.49 | 58.8% | 9.3% | 47.53 | 80.2% | 10.2% |
| 25Δ | 54.98 | 49.9% | 6.6% | 48.47 | 78.1% | 8.9% |
| 30Δ | 54.43 | 49.0% | 5.8% | 49.41 | 76.0% | 7.5% |
| 35Δ | 53.88 | 48.0% | 5.0% | 50.26 | 73.2% | 6.3% |
| 40Δ | 53.33 | 47.1% | 4.3% | 50.96 | 69.4% | 5.3% |
| 45Δ | 52.78 | 46.2% | 3.5% | 51.66 | 65.5% | 4.4% |
| 50Δ | 52.26 | 46.2% | 3.0% | 52.35 | 61.6% | 3.4% |
| 55Δ | 51.76 | 47.2% | 2.6% | 52.99 | 60.6% | 2.9% |
| 60Δ | 51.26 | 48.2% | 2.3% | 53.61 | 60.2% | 2.4% |
| 65Δ | 50.76 | 49.3% | 1.9% | 54.24 | 59.9% | 2.0% |
| 70Δ | 50.26 | 50.3% | 1.6% | 54.86 | 59.5% | 1.5% |
| 75Δ | ||||||
| 80Δ | 58.69 | 86.6% | 1.2% | |||
20Δ
- Pseudo strike
- 56.49
- IV
- 58.8%
- B/E move
- 9.3%
- Pseudo strike
- 47.53
- IV
- 80.2%
- B/E move
- 10.2%
25Δ
- Pseudo strike
- 54.98
- IV
- 49.9%
- B/E move
- 6.6%
- Pseudo strike
- 48.47
- IV
- 78.1%
- B/E move
- 8.9%
30Δ
- Pseudo strike
- 54.43
- IV
- 49.0%
- B/E move
- 5.8%
- Pseudo strike
- 49.41
- IV
- 76.0%
- B/E move
- 7.5%
35Δ
- Pseudo strike
- 53.88
- IV
- 48.0%
- B/E move
- 5.0%
- Pseudo strike
- 50.26
- IV
- 73.2%
- B/E move
- 6.3%
40Δ
- Pseudo strike
- 53.33
- IV
- 47.1%
- B/E move
- 4.3%
- Pseudo strike
- 50.96
- IV
- 69.4%
- B/E move
- 5.3%
45Δ
- Pseudo strike
- 52.78
- IV
- 46.2%
- B/E move
- 3.5%
- Pseudo strike
- 51.66
- IV
- 65.5%
- B/E move
- 4.4%
50Δ
- Pseudo strike
- 52.26
- IV
- 46.2%
- B/E move
- 3.0%
- Pseudo strike
- 52.35
- IV
- 61.6%
- B/E move
- 3.4%
55Δ
- Pseudo strike
- 51.76
- IV
- 47.2%
- B/E move
- 2.6%
- Pseudo strike
- 52.99
- IV
- 60.6%
- B/E move
- 2.9%
60Δ
- Pseudo strike
- 51.26
- IV
- 48.2%
- B/E move
- 2.3%
- Pseudo strike
- 53.61
- IV
- 60.2%
- B/E move
- 2.4%
65Δ
- Pseudo strike
- 50.76
- IV
- 49.3%
- B/E move
- 1.9%
- Pseudo strike
- 54.24
- IV
- 59.9%
- B/E move
- 2.0%
70Δ
- Pseudo strike
- 50.26
- IV
- 50.3%
- B/E move
- 1.6%
- Pseudo strike
- 54.86
- IV
- 59.5%
- B/E move
- 1.5%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 58.69
- IV
- 86.6%
- B/E move
- 1.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 51.48% | |
| 50.26% | |
| 51.69% | |
| 51.63% | |
| 51.23% | |
| 52.47% | |
| 54.53% | |
| 53.02% | |
| 55.67% | |
| 55.38% |
Biotechnology
TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.
More →TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes for cancer patients. The…
More →UNCY
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for kidney diseases, particularly in the management of hyperphosphatemia.…
More →UPB
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. The company is…
More →URGN
Description unavailable
More →VANI
Vivani Medical Inc. (VANI) is a pioneering biotechnology firm focused on revolutionizing chronic disease management through its cutting-edge drug delivery systems. The company…
More →